[ad_1]
NEW YORK, Oct. 10, 2022 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ:CNTA) and certain of its officers and directors. The class action, filed in the United States District Court for the Central District of Californiaand docketed under 22-cv-07030, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Centessa American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about May 282021 (the “IPO” or “Offering”); and/or (b) Centessa securities between May 28, 2021 and June 1, 2022both dates inclusive (the “Class Period”). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 (the “Securities Act”) and the Securities Exchange Act of 1934 (the “Exchange Act”).
If you are a shareholder who purchased or otherwise acquired Centessa ADSs pursuant and/or traceable to the Offering Documents for the Company’s IPO, and/or Centessa securities during the Class Period, you have until November 28, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or…
Full story available on Benzinga.com
[ad_2]
Source link
